Reference
Aarts MJ, et al. Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia. Journal of Clinical Oncology : 28 Oct 2013. Available from: URL: http://dx.doi.org/10.1200/JCO.2012.48.3644
Rights and permissions
About this article
Cite this article
What is an ICER without QALYs gained?. PharmacoEcon Outcomes News 691, 5 (2013). https://doi.org/10.1007/s40274-013-0858-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0858-8